Akebia Therapeutics, Inc.

The US Food and Drug Administration maintained a high rate of complete response letter actions for novel agent applications in 2024, but recent history suggests that many of the 16 CRL recipients will

The new drugs that hit the market in 2024 included medicines to address an array of high unmet medical need, but the US Food and Drug Administration approval of several drugs for liver disease put a s

The new drugs that hit the market in 2024 included medicines to address an array of high unmet medical need, but the US Food and Drug Administration approval of several drugs for liver disease put a s

The US Food and Drug Administration leveraged safety information from two other same-in-class drugs in its review of Akebia Therapeutics, Inc. ’s Vafseo (vadadustat) for chronic kidney disease patien